GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » Equity-to-Asset

Defence Therapeutics (XCNQ:DTC) Equity-to-Asset : -3.43 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Defence Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$-2.30 Mil. Defence Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was C$0.67 Mil.

The historical rank and industry rank for Defence Therapeutics's Equity-to-Asset or its related term are showing as below:

XCNQ:DTC' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.7   Med: 0.63   Max: 0.98
Current: -3.43

During the past 3 years, the highest Equity to Asset Ratio of Defence Therapeutics was 0.98. The lowest was -4.70. And the median was 0.63.

XCNQ:DTC's Equity-to-Asset is ranked worse than
95.59% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs XCNQ:DTC: -3.43

Defence Therapeutics Equity-to-Asset Historical Data

The historical data trend for Defence Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics Equity-to-Asset Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22
Equity-to-Asset
0.98 0.98 -0.54

Defence Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.10 -4.70 0.42 -0.28 -3.43

Competitive Comparison of Defence Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Defence Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Defence Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Defence Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Defence Therapeutics's Equity-to-Asset falls into.



Defence Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Defence Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Jun. 2022 is calculated as

Equity to Asset (A: Jun. 2022 )=Total Stockholders Equity/Total Assets
=-0.388/0.72
=

Defence Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-2.295/0.669
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Defence Therapeutics  (XCNQ:DTC) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Defence Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Defence Therapeutics (XCNQ:DTC) Business Description

Traded in Other Exchanges
Address
200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.

Defence Therapeutics (XCNQ:DTC) Headlines

From GuruFocus

Solo Brands Acquires TerraFlame

By Business Wire Business Wire 05-11-2023

Solo Brands, Inc. Announces Participation in the 2023 ICR Conference

By Business Wire Business Wire 01-03-2023

Solo Stove Unveils Inaugural Ambassador Team

By PRNewswire 01-22-2024

Solo Brands, Inc. Announces Secondary Offering of Class A Common Stock

By Business Wire Business Wire 05-11-2023

Solo Brands to Participate in Fireside Chat at SHARE Series Event

By Business Wire Business Wire 05-22-2023